Literature DB >> 31527026

A practical thrice weekly ertapenem in hemodialysis patients.

Yune-Fang Ueng1,2,3,4, Hong-Jaan Wang5, Shiao Chi Wu6, Yee-Yung Ng7,8.   

Abstract

Change of ertapenem dosage from 500 mg daily to thrice weekly after each hemodialysis session can maintain the plasma concentration above 2 mg/L, and be practical in hemodialysis patients.
Copyright © 2019 American Society for Microbiology.

Entities:  

Year:  2019        PMID： 31527026      PMCID： PMC6879214          DOI： 10.1128/AAC.01427-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  A practical thrice weekly Ertapenem dosage regime for chronic hemodialysis patients?

Authors:  Charles J C Geerlings; Peter de Man; Arie P Rietveld; Daniel J Touw; Jan W Cohen Tervaert
Journal:  Clin Nephrol       Date:  2013-10       Impact factor: 0.975

2.  The recommended dose of ertapenem poses a potential risk for central nervous system toxicity in haemodialysis patients - case reports and literature reviews.

Authors:  K-H Lee; Y-F Ueng; C-W Wu; Y-C Chou; Y-Y Ng; W-C Yang
Journal:  J Clin Pharm Ther       Date:  2014-12-09       Impact factor: 2.512

3.  A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection.

Authors:  Scott E Briscoe; Brett C McWhinney; Jeffrey Lipman; Jason A Roberts; Jacobus P J Ungerer
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-09-16       Impact factor: 3.205

4.  Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis.

Authors:  Goutam C Mistry; Anup K Majumdar; Suzanne Swan; Domenic Sica; Alison Fisher; Yang Xu; Michael Hesney; Liwen Xi; John A Wagner; Paul J Deutsch
Journal:  J Clin Pharmacol       Date:  2006-10       Impact factor: 3.126

5.  In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains.

Authors:  R N Jones
Journal:  J Chemother       Date:  2001-08       Impact factor: 1.714

6.  Ertapenem-associated seizures in a peritoneal dialysis patient.

Authors:  Arnold H Seto; Jessica C Song; Steven S Guest
Journal:  Ann Pharmacother       Date:  2005-01-11       Impact factor: 3.154

7.  Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration.

Authors:  Rachel F Eyler; A Mary Vilay; Ahmed M Nader; Michael Heung; Melissa Pleva; Kevin M Sowinski; Daryl D DePestel; Fritz Sörgel; Martina Kinzig; Bruce A Mueller
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

8.  In vitro activity of ertapenem against selected respiratory pathogens.

Authors:  A Marchese; L Gualco; A M Schito; E A Debbia; G C Schito
Journal:  J Antimicrob Chemother       Date:  2004-10-07       Impact factor: 5.790

9.  Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis.

Authors:  Olaf Burkhardt; Carsten Hafer; Anita Langhoff; Volkhard Kaever; Vipul Kumar; Tobias Welte; Hermann Haller; Danilo Fliser; Jan T Kielstein
Journal:  Nephrol Dial Transplant       Date:  2008-08-23       Impact factor: 5.992

10.  Acute prolonged neurotoxicity associated with recommended doses of ertapenem in 2 patients with advanced renal failure.

Authors:  Min-Jie Wen; Chih-Chien Sung; Tom Chau; Shih-Hua Lin
Journal:  Clin Nephrol       Date:  2013-12       Impact factor: 0.975
View more
  2 in total

1.  Treatment of recurrent urinary tract infections in anuric hemodialysis patient, do we really need antimicrobial urinary concentration?

Authors:  Wasim S El Nekidy; Derrick Soong; Mohamad Mooty; Islam M Ghazi
Journal:  IDCases       Date:  2020-03-21

Review 2.  Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis.

Authors:  Christo Cimino; Yvonne Burnett; Nikunj Vyas; Anne H Norris
Journal:  Drugs       Date:  2021-02-16       Impact factor: 11.431
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.